Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CFO Christopher R. Cline sold 5,192 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the completion of the sale, the chief financial officer now owns 90,038 shares of the company’s stock, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Travere Therapeutics Stock Up 4.4 %
Shares of TVTX stock traded up $0.88 on Tuesday, hitting $21.10. The company’s stock had a trading volume of 987,233 shares, compared to its average volume of 1,250,242. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -4.64 and a beta of 0.72. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $21.56. The firm’s fifty day moving average price is $18.69 and its 200-day moving average price is $15.47.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Travere Therapeutics in the 4th quarter worth approximately $53,000. CWM LLC lifted its stake in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the last quarter. Quarry LP acquired a new position in Travere Therapeutics in the 3rd quarter valued at $105,000. Sei Investments Co. bought a new position in Travere Therapeutics in the 2nd quarter worth $117,000. Finally, Diversified Trust Co bought a new position in Travere Therapeutics in the 3rd quarter worth $161,000.
Analyst Ratings Changes
View Our Latest Report on TVTX
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
See Also
- Five stocks we like better than Travere Therapeutics
- How to Calculate Stock Profit
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.